Ghent University Academic Bibliography

Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)

C. Friedman, A. De Burgh Williams, J. S. Lopez, K. Ouali, M. R. Middleton, F. Thistlethwaite, O. Hamid, B. Izar, V. Moreno Garcia, M. L. Johnson, et al.

(2024) ANNALS OF ONCOLOGY. In Annals of Oncology 35(Supplement 2). p.S569-S570

Add to list

Inference failure with synthetic arms : empirical application to phase III oncology trials

Alexander Decruyenaere (UGent) , Heidelinde Dehaene (UGent) , Paloma Rabaey (UGent) , Charles Polet (UGent) , Johan Decruyenaere (UGent) , Toon Demeester (UGent) , Stijn Vansteelandt (UGent) and Sylvie Rottey (UGent)

(2024) ANNALS OF ONCOLOGY. In Annals of Oncology 35(Supplement 2). p.S526-S527

Add to list

Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+oropharyngeal cancer that progressed with prior anti-PD-1 therapy

A. Kong, C. Even, B. Aguilera, M. Klein Hesselink, S. Visscher, C. H. Chung, J. C. Park, D. R. Adkins, S. Salas, K. J. Harrington, et al.

(2024) ANNALS OF ONCOLOGY. In Annals of Oncology 35(Supplement 2). p.S627-S628

Add to list

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors : results from phase I dose exploration5

J. Rodon, H. Prenen, A. Sacher, M. Villalona-Calero, N. Penel, A. El Helali, Sylvie Rottey (UGent) , N. Yamamoto, F. Ghiringhelli, M. E. Goebeler, et al.

(2024) ANNALS OF ONCOLOGY. 35(12). p.1138-1147

Add to list

Conference Paper

Divergent fates: The ambiguous role of M2-like TAMs in oropharyngeal cancer

Michael Saerens (UGent) , Tijl Vermassen (UGent) , Jens Debacker (UGent) , Wouter Huvenne (UGent) , David Creytens (UGent) and Fleur Cordier (UGent)

(2024) In Annals of Oncology 35(S2).

Add to list

First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation

J. Heymach, N. Kotecki, H. Prenen, G. Alonso, C.R. Lindsay, M. Barve, C. Thamer, S. Eigenbrod-Giese, M.A. Marotti and Griet Van Lancker (UGent)

(2023) ANNALS OF ONCOLOGY. In Annals of Oncology 34(Supplement 2). p.S468-S468

Add to list

Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3

J. Mazieres, M. Duruisseaux, H. Curcio, C. Morizane, R. Galot, Sylvie Rottey (UGent) , J. A. Stratmann, Y. Ma, M. Bouzaggou, L. Geng, et al.

(2023) ANNALS OF ONCOLOGY. In Annals of Oncology 34(Supplement 2). p.S1076-S1077

Add to list

Current care for patients on oral anticancer therapy through a different lens : assessment from a patient and healthcare professional perspective

Ann Van Hecke (UGent) , Lise-Marie Kinnaer (UGent) , V. Foulon and Ilyse Kenis

(2023) ANNALS OF ONCOLOGY. In Annals of Oncology 34(Supplement 2). p.S1236-S1236

Add to list

Mentoring programs for specialised and advanced practice nurses : a systematic review

Isabel Vlerick (UGent) , Elsie Decoene (UGent) , Ann Van Hecke (UGent) , Ben Delbaere, A. Coolbrandt and Lise-Marie Kinnaer (UGent)

(2023) ANNALS OF ONCOLOGY. In Annals of Oncology 34(Supplement 2). p.S1248-S1248

Add to list

Dynamics and processes influencing role integration of advanced practice nurses and nurse navigators in oncology teams

Isabel Vlerick (UGent) , Ann Van Hecke (UGent) , Soumaya Akhayad (UGent) , Elsie Decoene (UGent) , Michiel Daem (UGent) and Lise-Marie Kinnaer (UGent)

(2023) ANNALS OF ONCOLOGY. In Annals of Oncology 34(Supplement 2). p.S1250-S1250

Academic Bibliography

Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)

Inference failure with synthetic arms : empirical application to phase III oncology trials

Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+oropharyngeal cancer that progressed with prior anti-PD-1 therapy

First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors : results from phase I dose exploration5

Divergent fates: The ambiguous role of M2-like TAMs in oropharyngeal cancer

First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation

Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3

Current care for patients on oral anticancer therapy through a different lens : assessment from a patient and healthcare professional perspective

Mentoring programs for specialised and advanced practice nurses : a systematic review

Dynamics and processes influencing role integration of advanced practice nurses and nurse navigators in oncology teams

Contents

Support

Contact